Bright Minds Biosciences Inc. Common Stock (DRUG)
Stock · NASDAQ · Health Care
$51.46as of 10/16/2026
Price chart
Active signals
DRUG Signal Track Record
How signals performed across all stocks →What DRUG's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 39 | +0.5% | 54% | October 7, 2026 |
| Bollinger Band Breakout | 23 | -3.0% | 35% | July 9, 2026 |
| Bollinger Band Breakdown | 21 | -4.9% | 43% | September 25, 2026 |
| 200-Day Moving Average TouchActive now | 7 | -17.1% | 29% | August 14, 2026 |
| Any 20-session window (baseline) | -3.7% | 43% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About DRUG
Bright Minds Biosciences Inc., a biotechnology company, develops therapeutics to improve the lives of patients with severe and life-altering diseases in the United States. Its portfolio includes 5-HT2 Receptors, which are serotonin agonists for epilepsy and neuropsychiatric disorders; and BMB-101, which has completed phase 1 trial for undisclosed seizure disorder and is in phase 2 clinical trials for the developmenta…
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Employees
- 26
- Website
- brightmindsbio.com/
Fundamentals
- 1-day range
- $51.25$55.67
- Market cap
- $792.81M
- P/E (trailing)
- —
- P/E (forward)
- -9.43
- EPS (trailing)
- $-2.90
- Dividend yield
- —
- Beta
- 2.40
- Avg. volume
- 149.8K
Forecasts
6 analyst ratings
Bright Minds Biosciences Inc. Common Stock Competitors
Chosen by industry and closest market cap.
- DRUGBright Minds Biosciences Inc. Common Stock$51.3▼ 5.37%Market cap $792.81MP/E —$68.02$170
- CLYMClimb Bio Inc. Common Stock$9.82▼ 9.99%Market cap $801.68MP/E —$1.64$18.33
- MNPRMonopar Therapeutics Inc. Common Stock$69.27▼ 3.52%Market cap $805.29MP/E —$50.07$124.82
- PHARPharming Group N.V. ADS each representing 10 ordinary shares$9.36▼ 2.80%Market cap $766.28MP/E 73.41$0.8338$1.82
- KURAKura Oncology Inc. Common Stock$9.08▼ 6.39%Market cap $823.83MP/E —$7.36$13.9
- CYRXCryoPort Inc. Common Stock$16.84▼ 1.35%Market cap $741.42MP/E —$7.61$18.36
- ACRSAclaris Therapeutics Inc. Common Stock$3.28▼ 6.02%Market cap $850.55MP/E —$1.74$6.6
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| DRUG Bright Minds Biosciences Inc. Common Stock | $792.81M | — | $51.3 | ▼ 5.37% | $68.02$170 |
| CLYM Climb Bio Inc. Common Stock | $801.68M | — | $9.82 | ▼ 9.99% | $1.64$18.33 |
| MNPR Monopar Therapeutics Inc. Common Stock | $805.29M | — | $69.27 | ▼ 3.52% | $50.07$124.82 |
| PHAR Pharming Group N.V. ADS each representing 10 ordinary shares | $766.28M | 73.41 | $9.36 | ▼ 2.80% | $0.8338$1.82 |
| KURA Kura Oncology Inc. Common Stock | $823.83M | — | $9.08 | ▼ 6.39% | $7.36$13.9 |
| CYRX CryoPort Inc. Common Stock | $741.42M | — | $16.84 | ▼ 1.35% | $7.61$18.36 |
| ACRS Aclaris Therapeutics Inc. Common Stock | $850.55M | — | $3.28 | ▼ 6.02% | $1.74$6.6 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- Wolfe Research Initiates Coverage On Bright Minds Biosciences with Outperform Rating, Announces Price Target of $150benzinga · 10/15/2026
- Bright Minds Biosciences And 2 More Canadian Biotech StocksYahoo · 10/8/2026
- Bright Minds Biosciences to Participate in the 2026 FPWR Research Symposium and PWS Family ConferenceYahoo · 9/30/2026
- Auxly Cannabis Group And 2 Other Canadian Biotech Stocks To WatchYahoo · 9/30/2026
- 3 Small Cap Stocks With Strong Revenue Growth And Low DebtYahoo · 9/16/2026
Insider Activity
Insider Actions →- Cormorant Asset Management, LP · April 28, 2026 · Sale109.3K @ $89.5
Institutional Ownership
March 31, 2026
- Total shares held
- 9.11M
- Total value held
- $664.32M
- Institutional holders
- 89
- Unknown1.28M
- Unknown1.06M
- Unknown621.9K
- Unknown557.2K
- Unknown539.7K
- Unknown495.7K
- Unknown492.3K
- Unknown432.5K
- Unknown377.5K
- Unknown297.2K
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 16, 2026
Bright Minds Biosciences Gains Attention from Wolfe Research
Wolfe Research has started coverage of Bright Minds Biosciences, giving it an outperform rating and a price target of $150. The coverage comes as a Canadian biotech stock that is trading significantly below its fair value, up to 93% below, according to a recent Yahoo report. The new rating highlights the company’s potential relative to its peers. Investors are noting the price target in the context of the stock’s 52‑week range of $68.02 to $170.00.
Bright Minds Biosciences Gains Attention from Wolfe Research. Wolfe Research has started coverage of Bright Minds Biosciences, giving it an outperform rating and a price target of $150. The coverage comes as a Canadian biotech stock that is trading significantly below its fair value, up to 93% below, according to a recent Yahoo report. The new rating highlights the company’s potential relative to its peers. Investors are noting the price target in the context of the stock’s 52‑week range of $68.02 to $170.00.